TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02494596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Study: NCT05530057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation.
Study: NCT03222427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C415N3] LY3314814
Description: Administered as an IV infusion
Study: NCT03820557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo Decision Counseling Program
Study: NCT00893516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHOP + CD4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Study: NCT02750059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/3TC/EFV + Telmisartan
Description: The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC/EFV only
Description: Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
Study: NCT02736747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03762304

Intervention type: OTHER
Intervention: Household blood pressure screening with care encouragement
Description: During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months.
Study: NCT01894126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-way SMS Dialogue

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-way SMS Messaging
Study: NCT00748228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary sodium
Description: 10 mEq/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary sodium
Description: 300 mEq/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary sodium
Description: 150 mEq/day dietary sodium
Study: NCT02337309

Intervention type: DRUG
Group type: OTHER
Intervention: SF1126
Description: SF1126 in IV form with be given to patients on this study.
Study: NCT04729660

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
Study: NCT04346927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: 15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise brochure
Description: 15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
Study: NCT02816905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % Dexamethasone
Description: 20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Fluorometholone
Description: 20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Rimexolone
Description: 40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
Study: NCT04529174

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CardioLux™HDL
Description: Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)
Study: NCT01253486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease-related Expressive writing
Description: Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
Study: NCT04274296

Intervention type: DEVICE
Intervention: Activation of Advisory
Description: Advisory is activated which will show if driving pressure is greater or equal 15
Study: NCT02440334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
Study: NCT01253486

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Traditional expressive writing
Description: Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Neutral writing
Description: Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
Study: NCT03640884

Intervention type: DRUG
Intervention: Xueshuantong-Injection
Description: Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
Study: NCT03008187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL24/MEN1703
Description: SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Study: NCT01590147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: receive YST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive YST or CE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Receive YST or CE
Study: NCT01760642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 600 mg PO
Study: NCT01332461

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate combination
Description: Patients filling a prescription for fluticasone/salmeterol combination as index drug

Intervention type: DRUG
Intervention: Other maintenance Treatments (OMT)
Description: OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
Study: NCT03528499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Movement Training
Description: Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises
Description: Strengthening and stretching exercises.
Study: NCT00959660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: walking, treadmill and bicycle exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: walking, treadmill and bicycle exercise
Study: NCT01179516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets
Study: NCT00959660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Subjects will be provided meals and instructions for individual food selections.
Study: NCT01590147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive CE
Study: NCT00959660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: control group- continue their previously randomized life style
Study: NCT03885362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 and Abbott Freestyle Libre
Description: Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
Study: NCT01099943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Education, Decision Support Tools
Description: Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
Study: NCT00804063

Intervention type: PROCEDURE
Intervention: drawing blood sample
Description: fasting blood sample

Intervention type: PROCEDURE
Intervention: drawing blood sample
Description: fasting blood sample
Study: NCT00769288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-F-ara-deoxyuridine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study: NCT04033471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
Study: NCT02077270

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: electroacupuncture
Description: Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
Study: NCT01938066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Procellera
Description: bioelectric wound dressing

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: negative pressure therapy
Study: NCT03211572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Participants will take endocrine therapy for 2 weeks prior to surgery.
Study: NCT00548184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Monoclonal Antibody
Study: NCT01938066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: negative pressure therapy
Study: NCT01852435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CEOP-70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CEOP-90

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP-50
Study: NCT02134964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLT1177 Capsules
Description: OLT1177 Capsules are an experimental drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
Study: NCT02923635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wide local excision.
Description: Excision of breast cancer without integration of plastic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oncoplastic breast surgery.
Description: Integration of plastic techniques with oncological surgery for resection of breast cancer.
Study: NCT01911520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: Patients receive 2 mg/kg Sugammadex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: Patients receive 2 mg/kg Sugammadex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: Patients receive 2 mg/kg Sugammadex.
Study: NCT01179516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study: NCT03181997

Intervention type: DEVICE
Intervention: Native aortic valve
Description: Native valve, with any transcatheter heart valve type

Intervention type: DEVICE
Intervention: Native aortic valve
Description: Native valve, with any transcatheter heart valve type

Intervention type: PROCEDURE
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.

Intervention type: PROCEDURE
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
Study: NCT00634972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACULAR
Description: infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REFRESH TEARS
Description: infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00117819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]ß CIT and SPECT imaging
Description: To assess \[123I\]ß CIT and SPECT imaging
Study: NCT03844074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg, intravitreal injection
Study: NCT00769288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study: NCT01323478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 15 or 20 mg/day; tablets; orally
Study: NCT00653861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM™ Injectable Gel with Lidocaine
Description: Single treatment, volume determined by investigator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JUVÉDERM™ Injectable Gel
Description: Single treatment, volume determined by investigator
Study: NCT01018355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous device closure of patent foramen ovale
Description: Percutaneous device closure of patent foramen ovale

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous device closure of patent foramen ovale
Description: Percutaneous device closure of patent foramen ovale
Study: NCT00643994

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiosurgery
Description: 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
Study: NCT01325103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.